|
1）Regev-Yochay G, Bogaert D, Malley R, et al. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis. 2008; 47: 289-91
|
|
|
|
2）Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013; 188: 985-95
|
|
|
|
|
3）Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991; 325: 1453-60
|
|
|
|
|
|
4）Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010; 51: 1007-16
|
|
|
|
|
|
5）Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Chochurane datebase Syst Rev. 2013; 4: CD000422
|
|
|
|
|
|
6）Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008; 47: 1328-38
|
|
|
|
|
|
7）Maruyama T, Taguchi O, Niederman MS, et al. Efficacy of 23-valent pneumococcal vaccine in preventing pneumonia and improving survival in nursing home residents: double blind, randomized and placebo controlled trial. BMJ. 2010; 340: c1004
|
|
|
|
|
|
8）Kawakami K, Ohkusa Y, Kuroki R, et al. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine. 2010; 28: 7063
|
|
|
|
|
|
9）厚生科学審議会感染症分科会予防接種部会．ワクチン評価に関する小委員会 報告書．肺炎球菌ポリサッカライドワクチン（成人用）． 2011年3月11日
|
|
|
|
|
|
10）Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372: 1114-25
|
|
|
|
|
|
11）Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 201: 32-41
|
|
|
|
|
|
12）庵原俊明，菅 秀，浅田和豊．Hib，肺炎球菌，HPV及びロタウイルスワクチンの各ワクチンの有効性，安全性並びにその投与方法に関する基礎的・臨床的研究（厚生労働科学研究費補助金 新型インフルエンザ等新興・再興感染症研究事業 研究代表者：庵原俊明）平成25年度総括・分担研究者報告書. 2014. p.7-13
|
|
|
|
|
|
13）常 彬，前川順子．成人侵襲性肺炎球菌感染症由来株の細菌学的解析（厚生労働科学研究費補助金 新型インフルエンザ等新興・再興感染症研究事業 研究代表者：大石和徳）平成26年度総括・分担研究者報告書. 2015. p. 63-7
|
|
|
|
|
|
14）田村和代，早川路代，服部裕美，他．IASR 肺炎球菌特異抗体測定とその役割．2013; 34: 66-7
|
|
|
|
|
|
15）Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013; 31: 3577-84
|
|
|
|
|
|
16）Shiramoto M, Irie S, Juergens C, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≧50 years. An open-label trial. Hum Vaccin Immunother. 2014; 10: 1850-8
|
|
|
|
|
|
17）Jackson LA, Gurtman A, Rice K, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013; 31: 3585-93
|
|
|
|
|
|
18）Namkoong H, Funatsu Y, Oishi K, et al. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan: an open-labeled randomized study. Vaccine. 2015; 33: 327-32
|
|
|
|
|
|
19）Morimoto K, Suzuki M, Ishifuji T, et al. The burden and etiology of community-onset pneumonia in the aging Japanese population: a multi center prospective study. Plos One. 2015; 30: 10: e0122247
|
|
|
|
|
|
20）Tomczyk S, Bennett NM, Stoecker C, et al, Centers for Disease Control and Prevention （CDC）. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≧65 years: recommendations of the Advisory Committee on Immunization Practices （ACIP）. MMWR Morb Mortal Wkly Rep. 2014; 63: 822-5
|
|
|
|
|
|
21）Ohshima N, Nagai H, Matsui H, et al. Sustained functional serotype-specific antibody after primary and secondary vaccinations with a pneumococcal polysaccharide vaccine in elderly patients with chronic lung disease. Vaccine. 2014; 32: 1181-6
|
|
|
|
|